Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Hemicholinium
2. Hemicholinium 3
1. 312-45-8
2. Hemicholinium 3
3. Hemicholinium Bromide
4. Hemicholine
5. Hemicholinium Dibromide
6. Hemicholinium-3 Bromide
7. Hc-3
8. Hemicholinium 3 Dibromide
9. Hemicholinium-3 Dibromide
10. 65ny3i7zd0
11. Morpholinium, 2,2'-(1,1'-biphenyl)-4,4'-diylbis(2-hydroxy-4,4-dimethyl-, Dibromide
12. Morpholinium, 2,2'-(1,1'-biphenyl)-4,4'-diylbis(2-hydroxy-4,4-dimethyl-, Bromide (1:2)
13. Morpholinium, 2,2'-[1,1'-biphenyl]-4,4'-diylbis[2-hydroxy-4,4-dimethyl-, Dibromide
14. Hemicholinium 3 Dibromide; Hemicholinium Bromide; Hemicholinium Dibromide; Hemicholinium-3 Bromide
15. [3h]hemicholinium-3
16. Nsc-527583
17. [3h]-hemicholinium-3
18. Sr-01000075620
19. Einecs 206-227-3
20. Nsc 527583
21. Unii-65ny3i7zd0
22. [3h]hc-3
23. Prestwick_566
24. [3h]-hc-3
25. Hemicholiniumdibromide
26. Schembl564623
27. Chembl197027
28. Gtpl4493
29. Dtxsid80883358
30. Hms1569o07
31. Hms2096o07
32. Hms3261d18
33. Hms3713o07
34. Hms3885f21
35. Hy-b2152
36. Hemicholinium Dibromide [mi]
37. Tox21_500578
38. 2,2'-(4,4'-biphenylene)bis(2-hydroxy-4,4-dimethylmorpholinium Bromide)
39. 2,2'-(4,4'-biphenylene)bis(2-hydroxy-4,4-dimethylmorpholinium) Dibromide
40. Akos026750387
41. Ccg-220393
42. Ccg-221882
43. Lp00578
44. 2,2'-(1,1'-biphenyl)-4,4'-diylbis(2-hydroxy-4,4-dimethyl-morpholinium) Dibromide
45. Morpholinium, 2,2'-(1,1'-biphenyl)-4,4'-diylbis(2-hydroxy-4,4-dimethyl)-, Dibromide
46. Morpholinium, 2,2'-(4,4'-biphenylylene)bis(2-hydroxy-4,4-dimethyl-, Dibromide
47. Ncgc00093959-01
48. Ncgc00261263-01
49. Hemicholinium-3, Solid, >=95% (hplc)
50. Cs-0020304
51. Eu-0100578
52. Ft-0741707
53. H-108
54. J-018290
55. Sr-01000075620-1
56. Sr-01000075620-5
57. Q15409437
58. 2,2'-(biphenyl-4,4'-diyl)bis(2-hydroxy-4,4-dimethylmorpholin-4-ium) Bromide
59. 2-[4-[4-(2-hydroxy-4,4-dimethylmorpholin-4-ium-2-yl)phenyl]phenyl]-4,4-dimethylmorpholin-4-ium-2-ol;dibromide
60. 2-hydroxy-2-{4-[4-(2-hydroxy-4,4-dimethylmorpholin-4-ium-2-yl)phenyl]phenyl}-4,4-dimethylmorpholin-4-ium Dibromide
| Molecular Weight | 574.3 g/mol |
|---|---|
| Molecular Formula | C24H34Br2N2O4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 3 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 58.9 |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 544 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 2 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
Cholinergic Agents
Any drug used for its actions on cholinergic systems. Included here are agonists and antagonists, drugs that affect the life cycle of ACETYLCHOLINE, and drugs that affect the survival of cholinergic neurons. The term cholinergic agents is sometimes still used in the narrower sense of MUSCARINIC AGONISTS, although most modern texts discourage that usage. (See all compounds classified as Cholinergic Agents.)
Neurotransmitter Uptake Inhibitors
Drugs that inhibit the transport of neurotransmitters into axon terminals or into storage vesicles within terminals. For many transmitters, uptake determines the time course of transmitter action so inhibiting uptake prolongs the activity of the transmitter. Blocking uptake may also deplete available transmitter stores. Many clinically important drugs are uptake inhibitors although the indirect reactions of the brain rather than the acute block of uptake itself is often responsible for the therapeutic effects. (See all compounds classified as Neurotransmitter Uptake Inhibitors.)
ABOUT THIS PAGE
55
PharmaCompass offers a list of Hemicholinium-3 API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Hemicholinium-3 manufacturer or Hemicholinium-3 supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Hemicholinium-3 manufacturer or Hemicholinium-3 supplier.
PharmaCompass also assists you with knowing the Hemicholinium-3 API Price utilized in the formulation of products. Hemicholinium-3 API Price is not always fixed or binding as the Hemicholinium-3 Price is obtained through a variety of data sources. The Hemicholinium-3 Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A FT-0741707 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of FT-0741707, including repackagers and relabelers. The FDA regulates FT-0741707 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. FT-0741707 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A FT-0741707 supplier is an individual or a company that provides FT-0741707 active pharmaceutical ingredient (API) or FT-0741707 finished formulations upon request. The FT-0741707 suppliers may include FT-0741707 API manufacturers, exporters, distributors and traders.
FT-0741707 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of FT-0741707 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right FT-0741707 GMP manufacturer or FT-0741707 GMP API supplier for your needs.
A FT-0741707 CoA (Certificate of Analysis) is a formal document that attests to FT-0741707's compliance with FT-0741707 specifications and serves as a tool for batch-level quality control.
FT-0741707 CoA mostly includes findings from lab analyses of a specific batch. For each FT-0741707 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
FT-0741707 may be tested according to a variety of international standards, such as European Pharmacopoeia (FT-0741707 EP), FT-0741707 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (FT-0741707 USP).
